Cargando…

Explorative study of emerging blood biomarkers in progressive multiple sclerosis (EmBioProMS): Design of a prospective observational multicentre pilot study

BACKGROUND: Defining clinical and subclinical progression in multiple sclerosis (MS) is challenging. Patient history, expanded disability status scale (EDSS), and magnetic resonance imaging (MRI) all have shortcomings and may underestimate disease dynamics. Emerging serum biomarkers such as glial fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdelhak, Ahmed, Huss, Andre, Stahmann, Alexander, Senel, Makbule, Krumbholz, Markus, Kowarik, Markus C., Havla, Joachim, Kümpfel, Tania, Kleiter, Ingo, Wüstinger, Isabella, Zettl, Uwe K., Schwartz, Margit, Roesler, Romy, Friede, Tim, Ludolph, Albert C., Ziemann, Ulf, Tumani, Hayrettin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251538/ https://www.ncbi.nlm.nih.gov/pubmed/32478196 http://dx.doi.org/10.1016/j.conctc.2020.100574

Ejemplares similares

A Score Based on NfL and Glial Markers May Differentiate Between Relapsing–Remitting and Progressive MS Course
por: Huss, André, et al.
Publicado: (2020)

Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies
por: Huss, André, et al.
Publicado: (2020)

Diagnostic biomarkers in tear fluid: from sampling to preanalytical processing
por: Bachhuber, Franziska, et al.
Publicado: (2021)

CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort
por: Senel, Makbule, et al.
Publicado: (2019)

Stress cardiomyopathy associated with the first manifestation of multiple sclerosis: a case report
por: Rapp, Daniel, et al.
Publicado: (2020)

Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis
por: Jarius, Sven, et al.
Publicado: (2023)

Varicella zoster virus-induced neurological disease after COVID-19 vaccination: a retrospective monocentric study
por: Abu-Rumeileh, Samir, et al.
Publicado: (2021)

Safety and Tolerability of Plasma Exchange and Immunoadsorption in Neuroinflammatory Diseases
por: Dorst, Johannes, et al.
Publicado: (2020)

Cerebrospinal Fluid Immunoglobulin Kappa Light Chain in Clinically Isolated Syndrome and Multiple Sclerosis
por: Senel, Makbule, et al.
Publicado: (2014)

Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis
por: Robinson, Tilman, et al.
Publicado: (2020)

Tick-Borne Encephalitis: A Differential Pattern of Intrathecal Humoral Immune Response and Inflammatory Cell Composition Compared with Other Viral CNS Infections
por: Senel, Makbule, et al.
Publicado: (2020)

Human immunodeficiency virus and multiple sclerosis: a review of the literature
por: Stefanou, Maria-Ioanna, et al.
Publicado: (2019)

Bridging, switching or drug holidays – how to treat a patient who stops natalizumab?
por: Havla, Joachim, et al.
Publicado: (2013)

Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?
por: Abdelhak, Ahmed, et al.
Publicado: (2015)

Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial
por: Dorst, Johannes, et al.
Publicado: (2019)

Immunoadsorption and Plasma Exchange in Seropositive and Seronegative Immune-Mediated Neuropathies
por: Davies, Alexander J., et al.
Publicado: (2020)

The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS)
por: Brettschneider, Johannes, et al.
Publicado: (2010)

Association of Serum GFAP with Functional and Neurocognitive Outcome in Sporadic Small Vessel Disease
por: Huss, André, et al.
Publicado: (2022)

Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?
por: Abdelhak, Ahmed, et al.
Publicado: (2019)

Clinical associations and characteristics of the polyspecific intrathecal immune response in elderly patients with non-multiple sclerosis chronic autoimmune-inflammatory neurological diseases – a retrospective cross-sectional study
por: Brauchle, Felix, et al.
Publicado: (2023)

Differentiation of viral and autoimmune central nervous system inflammation by kynurenine pathway
por: Luo, Yi, et al.
Publicado: (2021)

CSF profile in primary progressive multiple sclerosis: Re-exploring the basics
por: Abdelhak, Ahmed, et al.
Publicado: (2017)

Guillain–Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases
por: Abu-Rumeileh, Samir, et al.
Publicado: (2020)

The Sexual Dimorphism in Cerebrospinal Fluid Protein Content Does Not Affect Intrathecal IgG Synthesis in Multiple Sclerosis
por: Castellazzi, Massimiliano, et al.
Publicado: (2022)

Primary Progressive Multiple Sclerosis: Putting Together the Puzzle
por: Abdelhak, Ahmed, et al.
Publicado: (2017)

Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?
por: Havla, Joachim, et al.
Publicado: (2021)

Treatment of progressive multiple sclerosis with high-dose all-trans retinoic acid – no clear evidence of positive disease modifying effects
por: Ruschil, Christoph, et al.
Publicado: (2021)

Tumefactive demyelinating CNS lesion in a 60-year-old woman with familial Mediterranean fever
por: Trostel, Constanze, et al.
Publicado: (2021)

Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response
por: Stellmann, Jan-Patrick, et al.
Publicado: (2017)

Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4
por: Kessler, Christoph, et al.
Publicado: (2022)

Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Petereit, Hela-Felicitas, et al.
Publicado: (2021)

Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab
por: Kemmerer, C. L., et al.
Publicado: (2020)

Inner Retinal Layer Changes Reflect Changes in Ambulation Score in Patients with Primary Progressive Multiple Sclerosis
por: Gernert, Jonathan A., et al.
Publicado: (2023)

Development of an ultrasensitive microfluidic assay for the analysis of Glial fibrillary acidic protein (GFAP) in blood
por: Fazeli, Badrieh, et al.
Publicado: (2023)

Soluble Beta-Amyloid Precursor Protein Is Related to Disease Progression in Amyotrophic Lateral Sclerosis
por: Steinacker, Petra, et al.
Publicado: (2011)

IgG Antibodies against Measles, Rubella, and Varicella Zoster Virus Predict Conversion to Multiple Sclerosis in Clinically Isolated Syndrome
por: Brettschneider, Johannes, et al.
Publicado: (2009)

Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions
por: Kleiter, Ingo, et al.
Publicado: (2018)

Serum neurofilament light chain: No clear relation to cognition and neuropsychiatric symptoms in stable MS
por: Aktas, Orhan, et al.
Publicado: (2020)

Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75
por: Krumbholz, Markus, et al.
Publicado: (2015)

Serum GFAP as a biomarker for disease severity in multiple sclerosis
por: Abdelhak, A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_s87s58e0s5h58ao47dmntbfss6